KLRK1 and neoplasm: Several clinical interventions have been demonstrated to up-regulate NKG2D ligands expression on tumor cells and enhance susceptibility to NK cells, including chemotherapy, radiotherapy and HDAC-1[22], Proteasome inhibitor[23].